Citations

Clear

513 citation(s) found for "Ta, Casey".

A stochastic multicompartment model of hemostasis and oxygenation during trauma resuscitation as a platform for in silico trials of transfusion
Vieni, Casey , Yazer, Mark H. , Seheult, Jansen N. , Seheult, Jansen N

Mayo Clinic

American Journal of Clinical Pathology | November 29, 2023 | Volume: 160 | Issue: Supplement_1 | Pages: S121-S122

10.1093/ajcp/aqad150.265 Get It

Abstract Uncontrolled hemorrhage accounts for up to 40% of trauma related mortality, and approximately 30% of trauma related deaths occur in the hospital within the first 1-4 hours of injury. The Advanced Trauma Life Support (ATLS) guidelines still recommend initial resuscitation with crystalloid fluid as an integral part of maintaining or restoring hemodynamic stability, but are starting to recognize the role of early resuscitation with blood products in patients with evidence of Class III and IV hemorrhage, in line with recent clinical trial and observational data. Although there is a growing body of evidence that early transfusion with blood products may be associated with improved survival compared with crystalloid infusion, the optimal transfusion strategy still remains unclear and is being actively investigated in clinical trials. In silico models of resuscitation offer a means to evaluate the effectiveness and safety of resuscitation protocols, including effects on body fluid compartment volumes, tissue oxygenation, and hemostatic factors. Here we describe our work extending earlier deterministic models of trauma resuscitation to incorporate hemodynamic, hemostatic, resuscitation, biomarker, and tissue-oxygenation domains into a single comprehensive model. Additionally, this model expands upon previous deterministic models to create a stochastic computational model of hemostatic resuscitation that accounts for variations in blood component composition and temporal features of transfusion therapy. Using this stochastic model, an in silico trial was piloted to compare conventional component therapy, i.e. red cell, platelet and plasma components, to cold-stored whole blood using the following starting assumptions: patient weight of 81.3±21.8 kg, hematocrit of 41.8±4.3%, initial bleeding rate between 50 and 150 mL/min, systolic blood pressure of 125±18 mmHg, fibrinogen of 293±88 mg/dL, international normalized ratio of 1.0±0.1 and platelet count of 239±62x109/L, with blood component and whole blood constituent distributions based on laboratory quality control data. This in silico trial demonstrated that resuscitation with whole blood was associated with a 28-minute reduction in the time spent in the critical window defined by platelet count <50x109/L, INR≥2, hemoglobin <9 g/dL and fibrinogen <150 mg/dL compared with conventional component resuscitation over the course of a 4 hour simulation (p<0.001 based on median regression). We demonstrate how stochastic models of hemostatic resuscitation can be used to perform in silico trials of resuscitation strategies. Our work can guide inclusion and exclusion criteria for future clinical trials and facilitate identification of patient subgroups most likely to benefit from certain resuscitation strategies. This work was partially funded by the AABB Foundation (formerly the National Blood Foundation).
The Impact of Nitrate Supplementation on the Peripheral Chemoreceptor Reflex to Hypoxia in Older Adults
Bock, Josh, Limberg, Jacqueline K. , Hughes, William E. , Kruse, Nicholas T. , Ueda, Kenichi , Casey, Darren P.

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 31 | Issue: S1 | Pages: No page available

10.1096/fasebj.31.1_supplement.867.1 Get It

Peripheral chemoreceptors located within the carotid bodies activate cardiorespiratory reflexes in response to hypoxia. Carotid body chemoreceptor activity has been shown to be enhanced in conditions such as congestive heart failure, hypertension, and possibly aging. Nitric oxide (NO) has been proposed as an inhibitory modulator of carotid body chemosensitivity in response to hypoxia. Additionally, NO bioavailability is often reduced with cardiovascular risk factors such as aging. In the present study, we tested the hypothesis that increasing NO bioavailability via dietary nitrate (NO 3 ) supplementation would reduce cardiorespiratory responses to hypoxia in older adults. A double‐blind, randomized, placebo‐controlled, cross‐over study design was used to evaluate minute ventilation (V E ) and heart rate (HR) responses to acute hypoxia in 7 older adults (66±2 years; 5M/2F) before and after 4 weeks of NO 3 supplementation (beetroot powder) and placebo (beetroot powder devoid of NO 3 ). On each study visit, subjects underwent two separate isocapnic hypoxic tests (self‐regulating, partial rebreathing system with 10% O 2 ). Subjects remained on 10% O 2 until SpO 2 reached ≤80%. The hypoxic exposures were separated by a 15‐minute washout period with the subjects breathing room air. V E , HR, and SpO 2 were continuously monitored throughout each hypoxic exposure. Data were grouped together using a 7‐breath average with the slope of the linear regression line for each dependent variable (V E and HR) versus SpO 2 serving as a measure of peripheral chemosensitivity. The slopes for the two hypoxia tests on each study visit were averaged and used for statistical comparisons. On study day one (true baseline) acute hypoxia increased both V E and HR ( P <0.05 for both). Four weeks of NO 3 supplementation reduced the hypoxic ventilatory response (−0.16 ± −0.05 vs. −0.06 ± −0.03 L/minute/%SpO 2 , P <0.05), whereas no change was observed following the placebo phase of the study (−0.14 ± −0.07 vs. −0.14 ± −0.08 L/minute/%SpO 2 , P=0.67). Additionally, the heart rate responses to acute hypoxia were also reduced following NO 3 supplementation (−0.49 ± −0.08 vs. −0.30 ± −0.05 beats/minute/%SpO 2 , P <0.05), but not with placebo (−0.54 ± −0.11 vs. −0.45 ± −0.08 beats/minute/%SpO 2 , P=0.21). Our preliminary findings suggest that supplementation of NO 3 to boost NO bioavailability in older adults blunts the cardiorespiratory responses to hypoxia. Future studies should examine the therapeutic potential of NO 3 in patient populations exhibiting exaggerated peripheral chemosensitivity. Support or Funding Information Research supported by Neogenis Inc.
Hepatic lipolysis by β‐adrenergic stimulation is inhibited by ethanol exposure
Weller, Shaun G. , McNiven, Mark A. , Schott, Micah B. , Rasineni, Karuna , Schulze, Ryan J. , Casey, Carol A.

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 31 | Issue: S1 | Pages: No page available

10.1096/fasebj.31.1_supplement.390.2 Get It

Steatotic hepatocytes accumulate profound numbers of large neutral lipid‐storage organelles called lipid droplets (LDs). The process by which the formation or utilization of these organelles are perturbed during NAFLD and NASH is poorly defined. EtOH consumption can also exacerbate these conditions markedly by yet unknown mechanisms. Thus, there is a critical need to understand lipolytic mechanisms for LD catabolism in hepatocytes. In adipocytes, catecholamines induce lipolysis through a β‐adrenergic/cAMP pathway that activates cytosolic lipases ATGL and HSL to catabolize LD triglycerides. Importantly, β‐adrenergic induction of LD catabolism has not been demonstrated in hepatocytes. Thus, the GOAL of this study was to determine whether hepatocytes, like adipocytes, also undergo cAMP‐mediated lipolysis in response to β‐adrenergic (β‐AR) stimulation. First, treatment of primary rat hepatocytes or Hep3B human hepatoma cells with the β‐AR agonist isoproterenol caused a 20–40% reduction in total cellular LD content within 24 hours. β‐AR induced LD loss was mimicked by the cAMP agonist forskolin/IBMX and was abrogated by the cAMP‐dependent protein kinase (PKA) inhibitor H89. In correlation, PKA activation following β‐AR stimulation was confirmed by FRET biosensors and biochemical analysis. β‐AR stimulation directly activated the lipolytic pathway, as evidenced by cAMP/PKA‐mediated phosphorylation of hormone sensitive lipase (HSL) and adipose triglyceide lipase (ATGL). In addition, pharmacological inhibitors against ATGL or HSL each blocked β‐AR induced LD loss, suggesting that lipase activation is critical for this process in stimulated cells. To examine whether β‐AR/cAMP stimulation triggered lipase recruitment directly to the LD, live‐cell imaging of Hep3B cells expressing either ATGL‐EGFP or HSL‐sfGFP showed that within 60 min of stimulation, each lipase was significantly displaced from the cytosol and recruited to the LD surface. This recruitment was blocked by the PKA inhibitor H89. Finally, to test if EtOH exposure attenuates the activation of lipolysis in hepatocytes, we isolated primary hepatocytes from rats fed a 6‐week ethanol‐containing Lieber‐DeCarli diet. Compared with controls, ethanol‐exposed hepatocytes showed a drastic inhibition in lipase activation and LD breakdown following β‐AR/cAMP stimulation. Remarkably, in ethanol‐metabolizing VA13 hepatocytes, ethanol insult completely prevented isoproterenol‐induced translocation of ATGL‐EGFP to the LD. In summary , these results show that β‐adrenergic stimulation mobilizes cytosolic lipases for LD breakdown in hepatocytes, and perturbation of this pathway could be a major consequence of chronic ethanol insult leading to fatty liver. Manipulation of this regulatory cascade could be useful in developing new therapies to attenuate fatty liver disease. Support or Funding Information This study was generously supported by funding from NIAAA 5R01AA020735 (MAM and CAC) and NIDDK 5R37DK044650 (MAM), T32DK007352‐36 (MBS), and P30DK084567 (Mayo Clinic Center for Cell Signaling in Gastroenterology).
Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration
Liu, Arthur , Pisaneschi, Federica , Boda, Akash R. , Ager, Casey R. , Piwnica‐Worms, David , Hong, David S. , Curran, Michael A. , Hong, David S , Curran, Michael A , Piwnica-Worms, David , Pisaneschi, Federica , Liu, Arthur J , Gammon, Seth T

Mayo Clinic

JCI Insight | November 21, 2023 | Volume: 9 | Issue: 1 | Pages: No page available

10.1172/jci.insight.169150 | PMID 37988164 Get It

We previously showed that ablation of tumor hypoxia can sensitize tumors to immune checkpoint blockade (ICB). Here, we used a Kras +/G12D TP53 +/R172H Pdx1-Cre –derived (KPC-derived) model of pancreatic adenocarcinoma to examine the tumor response and adaptive resistance mechanisms involved in response to 2 established methods of hypoxia-reducing therapy: the hypoxia-activated prodrug TH-302 and vascular endothelial growth factor receptor 2 (VEGFR-2) blockade. The combination of both modalities normalized tumor vasculature, increased DNA damage and cell death, and delayed tumor growth. In contrast with prior cancer models, the combination did not alleviate overall tissue hypoxia or sensitize these KPC tumors to ICB therapy despite qualitative improvements to the CD8 + T cell response. Bulk tumor RNA sequencing, flow cytometry, and adoptive myeloid cell transfer suggested that treated tumor cells increased their capacity to recruit granulocytic myeloid-derived suppressor cells (G-MDSCs) through CCL9 secretion. Blockade of the CCL9/CCR1 axis could limit G-MDSC migration, and depletion of Ly6G-positive cells could sensitize tumors to the combination of TH-302, anti–VEGFR-2, and ICB. Together, these data suggest that pancreatic tumors modulate G-MDSC migration as an adaptive response to vascular normalization and that these immunosuppressive myeloid cells act in a setting of persistent hypoxia to maintain adaptive immune resistance.
Investigating the Pathogenic Interplay of Alpha-Synuclein, Tau, and Amyloid Beta in Lewy Body Dementia: Insights from Viral-Mediated Overexpression in Transgenic Mouse Models
Lim, Melina J., Boschen, Suelen L. , Kurti, Aishe, Casey, Monica Castanedes, Phillips, Virginia , Fryer, John Denis , Jansen‐West, Karen , Petrucelli, Leonard , Delenclos, Marion , McLean, Pamela J. , Castanedes Casey, Monica, Phillips, Virginia R, Boschen, Suelen L , McLean, Pamela J , Dickson, Dennis W.

Mayo Clinic

Biomedicines | October 22, 2023 | Volume: 11 | Issue: 10 | Pages: 2863

10.3390/biomedicines11102863 | PMID 37893236 Get It

Lewy body dementia (LBD) is an often misdiagnosed and mistreated neurodegenerative disorder clinically characterized by the emergence of neuropsychiatric symptoms followed by motor impairment. LBD falls within an undefined range between Alzheimer’s disease (AD) and Parkinson’s disease (PD) due to the potential pathogenic synergistic effects of tau, beta-amyloid (Aβ), and alpha-synuclein (αsyn). A lack of reliable and relevant animal models hinders the elucidation of the molecular characteristics and phenotypic consequences of these interactions. Here, the goal was to evaluate whether the viral-mediated overexpression of αsyn in adult hTau and APP/PS1 mice or the overexpression of tau in Line 61 hThy1-αsyn mice resulted in pathology and behavior resembling LBD. The transgenes were injected intravenously via the tail vein using AAV-PHP.eB in 3-month-old hThy1-αsyn, hTau, or APP/PS1 mice that were then aged to 6-, 9-, and 12-months-old for subsequent phenotypic and histological characterization. Although we achieved the widespread expression of αsyn in hTau and tau in hThy1-αsyn mice, no αsyn pathology in hTau mice and only mild tau pathology in hThy1-αsyn mice was observed. Additionally, cognitive, motor, and limbic behavior phenotypes were not affected by overexpression of the transgenes. Furthermore, our APP/PS1 mice experienced premature deaths starting at 3 months post-injection (MPI), therefore precluding further analyses at later time points. An evaluation of the remaining 3-MPI indicated no αsyn pathology or cognitive and motor behavioral changes. Taken together, we conclude that the overexpression of αsyn in hTau and APP/PS1 mice and tau in hThy1-αsyn mice does not recapitulate the behavioral and neuropathological phenotypes observed in LBD.
S909 Efficacy of Upadacitinib in Patients With Crohn’s Disease Activity Index-Based Eligibility Criteria: Post Hoc Analysis of U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 Trials
Lichtenstein, Gary R. , DuVall, Aaron, Chapman, J. Casey, Lacerda, Ana P. , Anyanwu, Samuel I., Garrison, Andrew, Dubinsky, Marla C. , Rubin, David T. , Loftus, Edward V. , Regueiro, Miguel , Anyanwu, Samuel, O’Brien, Daniel J. , Liu, Jianzhong

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S678-S679

10.14309/01.ajg.0000953276.85317.47 Get It

Treatment of vitamin D deficiency in children
Johnson, Casey R. , Leopold, Kaitlin N., Thacher, Thomas D., Fischer, Philip R. , Leopold, Kaitlin , Thacher, Thomas D.

Mayo Clinic

Expert Review of Endocrinology & Metabolism | October 11, 2023 | Volume: 18 | Issue: 6 | Pages: 489-502

10.1080/17446651.2023.2270053 | PMID 37861060 Get It

Pathogenic variants in the Longitudinal Early‐onset Alzheimer's Disease Study cohort
Jackson, Trever, Rumbaugh, Malia, Eloyan, Ani , Abreu, Marco , Dage, Jeffrey L. , Snoddy, Casey, Faber, Kelley , Hammers, Dustin B. , Taurone, Alexander, Thangarajah, Maryanne, Aisen, Paul, Kramer, Joel H. , Kukull, Walter A. , Vemuri, Prashanthi , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen , Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S. , Carrillo, María C. , Rabinovici, Gil D. , Apostolova, Liana G. , Vemuri, Prashanthi , Day, Gregory S , Rabinovici, Gil D , Wingo, Thomas S , Dage, Jeffrey L , Nudelman, Kelly , Foroud, Tatiana , Hammers, Dustin B , Beckett, Laurel , Koeppe, Robert A. , Murray, Melissa E. , Toga, Arthur W. , Atri, Alireza , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Wolk, David A. , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | October 7, 2023 | Volume: 19 | Issue: S9 | Pages: No page available

10.1002/alz.13482 | PMID 37801072 Get It

AbstractIntroductionOne goal of the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) is to investigate the genetic etiology of early onset (40–64 years) cognitive impairment. Toward this goal, LEADS participants are screened for known pathogenic variants.MethodsLEADS amyloid‐positive early‐onset Alzheimer's disease (EOAD) or negative early‐onset non‐AD (EOnonAD) cases were whole exome sequenced (N = 299). Pathogenic variant frequency in APP, PSEN1, PSEN2, GRN, MAPT, and C9ORF72 was assessed for EOAD and EOnonAD. Gene burden testing was performed in cases compared to similar‐age cognitively normal controls in the Parkinson's Progression Markers Initiative (PPMI) study.ResultsPreviously reported pathogenic variants in the six genes were identified in 1.35% of EOAD (3/223) and 6.58% of EOnonAD (5/76). No genes showed enrichment for carriers of rare functional variants in LEADS cases.DiscussionResults suggest that LEADS is enriched for novel genetic causative variants, as previously reported variants are not observed in most cases.Highlights Sequencing identified eight cognitively impaired pathogenic variant carriers. Pathogenic variants were identified in PSEN1, GRN, MAPT, and C9ORF72. Rare variants were not enriched in APP, PSEN1/2, GRN, and MAPT. The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) is a key resource for early‐onset Alzheimer's genetic research
21 Feasibility of muscular fitness testing in cardiac rehabilitation with portable movement sensor technology
Scales, Robert , Paul, Frank, Filler, Casey, Song, Zeyu , Moore, Kaitlin , Tomah, Molly, Mariah, McCready, Repp, Kaley, Ivy, Cynthia , Fernandes, Regis, Taylor, Bryan J.

Mayo Clinic

Abstracts | October 6, 2023 | Volume: No volume available | Issue: No issue available | Pages: A12.1-A12

10.1136/heartjnl-2023-bacpr.19 Get It

KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response
Ager, Casey R. , Zhang, Mingxuan , Chaimowitz, Matthew G., Bansal, Shruti, Tagore, Somnath, Jugler, Collin , Rogava, Meri , McCann, Patrick J. , Spina, Catherine, Drake, Charles G. , Izar, Benjamin , Izar, Benjamin , Tagore, Somnath , Obradović, Aleksandar , Melms, Johannes C. , McCann, Patrick, Dallos, Matthew C. , McCann, Patrick J.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | September 1, 2023 | Volume: 11 | Issue: 9 | Pages: e006782

10.1136/jitc-2023-006782 | PMID 37657842 Get It

Current methods for biomarker discovery and target identification in immuno-oncology rely on static snapshots of tumor immunity. To thoroughly characterize the temporal nature of antitumor immune responses, we developed a 34-parameter spectral flow cytometry panel and performed high-throughput analyses in critical contexts. We leveraged two distinct preclinical models that recapitulate cancer immunoediting (NPK-C1) and immune checkpoint blockade (ICB) response (MC38), respectively, and profiled multiple relevant tissues at and around key inflection points of immune surveillance and escape and/or ICB response. Machine learning-driven data analysis revealed a pattern of KLRG1 expression that uniquely identified intratumoral effector CD4 T cell populations that constitutively associate with tumor burden across tumor models, and are lost in tumors undergoing regression in response to ICB. Similarly, a Helios-KLRG1+ subset of tumor-infiltrating regulatory T cells was associated with tumor progression from immune equilibrium to escape and was also lost in tumors responding to ICB. Validation studies confirmed KLRG1 signatures in human tumor-infiltrating CD4 T cells associate with disease progression in renal cancer. These findings nominate KLRG1+ CD4 T cell populations as subsets for further investigation in cancer immunity and demonstrate the utility of longitudinal spectral flow profiling as an engine of dynamic biomarker discovery.